Komori
Other Disclosures2784Alfresa Holdings CorporationTrading & Wholesale

セルリソーシズ株式会社 Begins Offering Research-Use Human Umbilical Cord- and Amniotic Membrane-Derived Mesenchymal Stromal Cells

Subsidiary セルリソーシズ株式会社 has begun offering human umbilical cord- and amnion-derived mesenchymal stromal cells sourced from medical institutions in Japan as research-use products. Kanto Chemical Co., Inc. and subsidiary アルフレッサ篠原化学株式会社 will serve as sales partners, and a system has been established to enable purchases through existing distribution channels.

Worth reading
78Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Human umbilical cord-derived mesenchymal stromal cellsHuman amnion-derived mesenchymal stromal cells
Applicable field (uses covered by this announcement)

Research and development related to regenerative medicine, including the development of regenerative medicine products, reagents and automated cell culture equipment

Launch date14 July 2026 (actual)
What the company reported numerically
Quantitative Effects

Cell count: at least 5×10^5 cells per vial. Volume: 1mL per vial

Relationship between the counterparty and the company
Alfresa Holdings Corporation2784
Relationship with the Company

アルフレッサ篠原化学株式会社 and セルリソーシズ株式会社 are subsidiaries of the Company. Kanto Chemical Co., Inc. is a partner sales distributor.

CounterpartyKanto Chemical Co., Inc.アルフレッサ篠原化学株式会社

Kanto Chemical Co., Inc.: A comprehensive reagent manufacturer providing analytical reagents, pharmaceutical ingredients, in vitro diagnostic products and electronic chemicals, among other products. It has an established business base with universities, research institutions and life sciences companies nationwide., アルフレッサ篠原化学株式会社: A subsidiary of Alfresa Holdings Corporation. Headquartered in Kochi, Kochi Prefecture, it sells clinical diagnostic reagents, pharmaceuticals, medical materials and hygiene products to hospitals and clinics, testing centers, universities and research institutions, primarily across the 4 prefectures of Shikoku.

Registration number and expiry date

License number for manufacturing specified cell-processed products: FA2230001. Expiration date: Not disclosed

Location (as indicated in this announcement)

Koriyama Cell Processing Center (detailed location: Not disclosed)

Impact on Business Performance

The impact on results for the current fiscal year is expected to be minor at this time. Over the medium to long term, the Company believes this will contribute to enhancing the corporate value of the Group.

The company does not address Contract Value / Offering price.

Announced details
ItemDetails
Names of Products / Services CoveredHuman umbilical cord-derived mesenchymal stromal cells, Human amnion-derived mesenchymal stromal cells
CounterpartyKanto Chemical Co., Inc., アルフレッサ篠原化学株式会社
Counterparty overviewKanto Chemical Co., Inc.: A comprehensive reagent manufacturer providing analytical reagents, pharmaceutical ingredients, in vitro diagnostic products and electronic chemicals, among other products. It has an established business base with universities, research institutions and life sciences companies nationwide., アルフレッサ篠原化学株式会社: A subsidiary of Alfresa Holdings Corporation. Headquartered in Kochi, Kochi Prefecture, it sells clinical diagnostic reagents, pharmaceuticals, medical materials and hygiene products to hospitals and clinics, testing centers, universities and research institutions, primarily across the 4 prefectures of Shikoku.
Relationship with the Companyアルフレッサ篠原化学株式会社 and セルリソーシズ株式会社 are subsidiaries of the Company. Kanto Chemical Co., Inc. is a partner sales distributor.
Launch date14 July 2026 (actual)
Applicable areaResearch and development related to regenerative medicine, including the development of regenerative medicine products, reagents and automated cell culture equipment
Registration number and expiry dateLicense number for manufacturing specified cell-processed products: FA2230001. Expiration date: Not disclosed
LocationKoriyama Cell Processing Center (detailed location: Not disclosed)
Quantitative EffectsCell count: at least 5×10^5 cells per vial. Volume: 1mL per vial
Impact on Business PerformanceThe impact on results for the current fiscal year is expected to be minor at this time. Over the medium to long term, the Company believes this will contribute to enhancing the corporate value of the Group.
Items this document does not state (8)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyLocation scaleUsage historySource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

A system for shipping these products from the Koriyama Cell Processing Center is now in place. The stated background and objectives are to expand the range of cells available for research and development into regenerative medicine products, reagents and automated cell culture equipment, and to contribute to a stable supply of human cell materials and the industrialization of cell therapies.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
セルリソーシズ株式会社 Begins Offering Research-Use Human Umbilical Cord- and Amniotic Membrane-Derived Mesenchymal Stromal Cells | Alfresa Holdings Corporation (2784) timely disclosure | Komori